迈克生物
(300463)
| 流通市值：45.77亿 | | | 总市值：56.29亿 |
| 流通股本：4.92亿 | | | 总股本：6.05亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,034,014,365.87 | 475,257,129.69 | 2,170,468,429.26 | 1,607,884,075.22 |
| 营业收入 | 1,034,014,365.87 | 475,257,129.69 | 2,170,468,429.26 | 1,607,884,075.22 |
| 二、营业总成本 | 1,008,213,833.27 | 471,357,185.17 | 2,158,960,092.16 | 1,517,055,095.03 |
| 营业成本 | 441,653,421.17 | 200,837,971.9 | 890,544,630.37 | 708,493,912.64 |
| 税金及附加 | 8,936,800.01 | 1,226,612.06 | 26,891,347.67 | 20,908,130.51 |
| 销售费用 | 290,501,862.53 | 132,808,003.33 | 684,307,986.28 | 429,409,902.81 |
| 管理费用 | 105,699,967.92 | 55,931,067.13 | 219,664,710.84 | 139,501,932.98 |
| 研发费用 | 142,185,001.6 | 70,655,701.75 | 317,943,913.34 | 206,458,830 |
| 财务费用 | 19,236,780.04 | 9,897,829 | 19,607,503.66 | 12,282,386.09 |
| 其中:利息费用 | 13,042,998.85 | 6,546,910.24 | 21,536,536.04 | 15,139,999.85 |
| 其中:利息收入 | 4,523,685.89 | 1,736,183.77 | 6,859,619.02 | 4,872,296.4 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -310,556.36 | -158,479.45 | -12,021,028.28 | -11,379,628.93 |
| 加:投资收益 | 833,811.77 | 208,064.09 | -267,435.35 | 598,403.77 |
| 资产处置收益 | 1,902,756.57 | 475,019.82 | -2,310,905.07 | 2,737,045.22 |
| 资产减值损失(新) | -12,082,793.61 | -993,470.92 | -39,155,960.32 | -12,176,584.04 |
| 信用减值损失(新) | -8,032,972.21 | 3,148,216.51 | -42,153,986.97 | -23,073,050.96 |
| 其他收益 | 7,837,387.91 | 3,494,129.95 | 23,641,108.06 | 14,449,236.91 |
| 四、营业利润 | 15,948,166.67 | 10,073,424.52 | -60,759,870.83 | 61,984,402.16 |
| 加:营业外收入 | 4,034,176.27 | 67,390.52 | 3,496,984.3 | 548,953.48 |
| 减:营业外支出 | 2,920,541.5 | 1,736,337.16 | 42,274,504.94 | 28,031,587.08 |
| 五、利润总额 | 17,061,801.44 | 8,404,477.88 | -99,537,391.47 | 34,501,768.56 |
| 减:所得税费用 | -12,550,076.07 | 1,801,543.87 | -58,043,283.18 | -8,522,315.21 |
| 六、净利润 | 29,611,877.51 | 6,602,934.01 | -41,494,108.29 | 43,024,083.77 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 29,611,877.51 | 6,602,934.01 | -41,494,108.29 | 43,024,083.77 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 34,256,956.93 | 8,986,063.15 | -35,826,985.88 | 37,103,351.99 |
| 少数股东损益 | -4,645,079.42 | -2,383,129.14 | -5,667,122.41 | 5,920,731.78 |
| 扣除非经常损益后的净利润 | 32,940,830.7 | 9,884,983.59 | 17,343,973 | 64,307,078.12 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 0.01 | -0.06 | 0.06 |
| (二)稀释每股收益 | 0.06 | 0.01 | -0.06 | 0.06 |
| 八、其他综合收益 | -1,264,807.02 | 19,257.97 | -15,250,936.63 | -15,058,213.16 |
| 归属于母公司股东的其他综合收益 | -1,264,807.02 | 19,257.97 | -15,250,936.63 | -15,058,213.16 |
| 九、综合收益总额 | 28,347,070.49 | 6,622,191.98 | -56,745,044.92 | 27,965,870.61 |
| 归属于母公司股东的综合收益总额 | 32,992,149.91 | 9,005,321.12 | -51,077,922.51 | 22,045,138.83 |
| 归属于少数股东的综合收益总额 | -4,645,079.42 | -2,383,129.14 | -5,667,122.41 | 5,920,731.78 |
| 公告日期 | 2026-07-31 | 2026-04-29 | 2026-04-29 | 2025-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |